Amsino International, Inc. Company Profile

Background

Established in 1993 and headquartered in Pomona, California, Amsino International, Inc. is a leading global medical device manufacturer dedicated to advancing healthcare worldwide. The company's mission is to improve the safety and effectiveness of patient care by developing, manufacturing, and distributing high-quality medical products. With over 25 years of experience, Amsino has earned the trust of healthcare professionals globally, operating multiple FDA-registered manufacturing and R&D facilities in China, and sales and marketing operations in the United States. The company employs approximately 2,000 individuals.

Key Strategic Focus

Amsino's strategic focus centers on delivering clinically superior medical devices across various product categories, including:

Suction and Fluid Management: RECEPTAL® systems offer simple, safe, and complete solutions.

Medication Delivery Systems: AMSafe® products prioritize safety in medication administration.

Enteral Feeding Systems: AMSure® systems optimize nutritional delivery.

Urological Care: AMSure® solutions aim to prevent infections.

Respiratory Therapy Systems: AMSure® products enhance oxygen delivery.

Surgical and Nursing Systems: AMSure® offers comprehensive solutions for surgical and nursing care.

The company targets diverse healthcare settings, including long-term care, home care, emergency medical services, physician offices, and hospitals.

Financials and Funding

Amsino International's estimated annual revenue is approximately $61.5 million, with an estimated revenue per employee of $305,945. The company has secured total funding of $32 million.

Pipeline Development

Amsino continually expands its product portfolio through innovation and strategic acquisitions. In November 2024, the company acquired MedXL Inc., a Canadian manufacturer specializing in prefilled syringes used in intravenous drug therapy. This acquisition added products such as Praxiject™ 0.9% sodium chloride injection USP prefilled syringes, CitraFlow™ sodium citrate prefilled syringes, and CitraFlow PLUS™ citrate-ethanol prefilled syringes to Amsino's offerings.

Technological Platform and Innovation

Amsino's commitment to innovation is evident in its proprietary technologies and scientific methodologies:

Proprietary Technologies: The company holds 52 US and China patents, reflecting its dedication to continuous innovation.

Scientific Methods: Amsino's vertical integration encompasses injection molding, mold building, tube extrusion, radio frequency sealing, ultrasonic welding, form-fill packaging, and EtO sterilization. This integration ensures quality control and efficient production.

Leadership Team

Amsino's leadership comprises experienced professionals:

Dr. Richard Y. Lee: Founder, Chairman, President, and CEO since 1993, with over 30 years in the medical device industry.

Mr. Peter Sun: Chief Financial Officer since 2008, with prior experience at Arasor International Limited and Avanex Corporation.

Mr. Frank Ling: Chief Operating Officer since 2012, overseeing manufacturing facilities in China and Vietnam.

Mr. Andrew Yi Zhang: President of China operations, with over 30 years in healthcare business development.

Mr. Jeff Reid: President of North America, with extensive experience in healthcare strategy and business development.

Mr. Chester Chai: Senior Vice President of Global Marketing and Business Development, with over 28 years in the medical device industry.

Mr. Chris Stevens: Executive Vice President of North America, with over 20 years in healthcare sales and business development.

Ms. Sherry Wang: Vice President of Operations, with a background in finance, logistics, and procurement.

Ms. Jane Gao: Vice President of R&D since 2012, with extensive experience in product development.

Mr. Paul Shen: Vice President of Quality Assurance, with a tenure at Amsino since 2001.

Ms. Ada Xie: Vice President of Contract Manufacturing Business Unit, with a focus on supply chain management.

Dr. Mei Zhang: Vice President of Engineering, with extensive experience in infusion pumps and disposable products.

Leadership Changes

In 2024, Chris Stevens returned to Amsino as Executive Vice President of North America, bringing over 20 years of experience in healthcare sales and business development.

Competitor Profile

Market Insights and Dynamics: The global medical device market is highly competitive, with significant growth potential driven by technological advancements and increasing healthcare demands.

Competitor Analysis:

Becton, Dickinson and Company (BD): A global medical technology company offering a broad range of medical devices, laboratory equipment, and diagnostic products.

Medtronic: A leading medical device company providing innovative solutions across various medical fields.

B. Braun Melsungen AG: A German medical and pharmaceutical device company specializing in healthcare products and services.

Cardinal Health: A healthcare services and products company offering customized solutions for hospitals, healthcare systems, pharmacies, and clinical laboratories.

Strategic Collaborations and Partnerships

Amsino has engaged in strategic alliances to enhance its market position:

MedXL Inc. Acquisition (2024): Expanded North American manufacturing capacity and product portfolio.

Alcor Scientific Collaboration (2013): Exclusive rights to market and distribute Alcor's Sentinel Enteral Feeding Pump in North America.

Covalon Technologies Alliance (2009): Joint pursuit of business development opportunities and manufacturing agreements.

Operational Insights

Amsino's vertical integration and global manufacturing facilities provide a competitive advantage in quality control and cost efficiency. The company's strategic acquisitions and partnerships have expanded its product offerings and market reach.

Strategic Opportunities and Future Directions

Amsino aims to continue its growth through innovation, strategic acquisitions, and partnerships. The company focuses on expanding its product portfolio, enhancing manufacturing capabilities, and strengthening its presence in key markets to meet the evolving needs of the healthcare industry.